共 16 条
[1]
Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Sutton MG,Sharpe N. Circulation . 2000
[2]
Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Yamamoto K,Ohki R,Lee RT,et al. Circulation . 2001
[3]
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Laufs U,La Fata V,Plutzky J,et al. Circulation . 1998
[4]
Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor,attenuates left ventricular remodeling and failure after experimental myocardial infarction. Hayashidani S,Tsutsui H,Shiomi T,et al. Circulation . 2002
[5]
Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Oi S,Haneda T,Osaki J,et al. European Journal of Pharmacology . 1999
[6]
Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Bauersachs J,Galuppo P,Fraccarollo D,et al. Circulation . 2001
[7]
Statin induced inhibition of the Rho-signaling pathway activates PPARαand induces HDL apoA-I. Martin G,Duez H,Blanquart C,et al. The Journal of Clinical Investigation . 2001
[8]
RhoGTPasesandsignal ingnetworks. VanAelstL,D′SouzaSchoreyC. Genes and Development . 1997
[9]
Modulating cardiac hypertrophy by manipulating myocardial lipid metabolism. Frey N,Olson EN. Circulation . 2002
[10]
Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Luo JD,Zhang WW,Zhang GP,et al. Clinical and Experimental Pharmacology and Physiology . 1999